In this case, the two patents at issue referred to antibodies that “bind to specific amino acid residues on PCSK9.” The dispute has been viewed as a test case for the concept of enablement in ...

[Robinson JG. Clinical Lipid Management;455a ] Monoclonal antibodies are large and complex proteins which are specific to their target; anti-PCSK9 mAbs are able to bind to the catalytic domain of ...

Amgen sought to convince SCOTUS that its core or “genus” patent on blockbuster PCSK9 inhibitor Repatha (evolocumab) was valid and, moreover, should extend to just about any antibody against ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Praluent inhibits the binding of PCSK9 to the LDL receptor and thereby increases the ... VelocImmune ® technology that yields optimized fully-human monoclonal antibodies. In addition to the U.S., ...

Enzyme-linked immunosorbent assays were used to compare serum concentrations of TMAO, apolipoprotein A4 (APOA4), and proprotein convertase subtilisin/kexin type 9 (PCSK9) between patients with ...

Praluent inhibits the binding of PCSK9 to the LDL receptor and thereby ... technology that yields optimized fully-human monoclonal antibodies. In addition to the U.S., Praluent is approved in ...

This anticompetitive practice shut out an innovative therapy from the PCSK9 marketplace, not based on clinical ... which produces optimized fully human antibodies and new classes of bispecific ...

This anticompetitive practice shut out an innovative therapy from the PCSK9 marketplace, not based on clinical merit or price. Because of Amgen’s size and unrelated product portfolio, their ...